Christophe Segalini

Christophe Segalini is a prominent figure in the pharmaceutical industry, currently serving as the Senior Vice President and Head of Global Value and Access at Idorsia Pharmaceuticals Ltd. He has been in this role since September 2019, where he is responsible for overseeing the company's strategies related to market access and ensuring that their products are accessible to patients globally.145

Professional Background

Segalini has extensive experience in the biopharmaceutical sector, having previously held significant positions at Bristol-Myers Squibb (B-MS), where he was instrumental in developing global market access capabilities. His leadership in this area has been recognized as pivotal for driving organizational effectiveness within the company.23

Expertise and Contributions

With a career spanning over 25 years, Segalini's expertise encompasses various business functions within the pharmaceutical industry, including commercial strategy, market access, and product lifecycle management. He is known for his strategic insight into market dynamics and his ability to navigate complex regulatory environments to facilitate product launches and access.2

Current Focus

At Idorsia, Segalini is actively involved in preparing for the launch of new products, including QUVIVIQ™ (daridorexant) and PIVLAZ™ (clazosentan), emphasizing his commitment to ensuring that innovative therapies reach patients effectively.14 His work not only focuses on market strategies but also on collaboration with research and development teams to align product offerings with patient needs.

In summary, Christophe Segalini is a seasoned executive whose leadership at Idorsia Pharmaceuticals is marked by a strong focus on global access strategies and operational excellence in the biopharmaceutical landscape.